Myong Gyong Lee

Title: Myong Gyong Lee: Innovator in CYP2D6 Metabolism Solutions

Introduction

Myong Gyong Lee is a notable inventor based in Palo Alto, California. He has made significant contributions to the field of pharmacology, particularly in the treatment of CYP2D6 alternative metabolizers. His innovative approach addresses the challenges posed by genetic variations in drug metabolism.

Latest Patents

Myong Gyong Lee holds a patent titled "Methods of treating CYP2D6 alternative metabolizers." This invention provides various methods that involve the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. The metabolism of these drug conjugates is redirected from CYP2D6 to alternative pathways. This advancement may alleviate issues associated with interpopulation variation resulting from genetic polymorphisms in the CYP2D6 gene. He has 1 patent to his name.

Career Highlights

Myong Gyong Lee is currently associated with Nektar Therapeutics, a company known for its innovative approaches in drug development. His work focuses on enhancing the efficacy and safety of medications through novel metabolic pathways.

Collaborations

Myong Gyong Lee collaborates with esteemed colleagues, including Michael A. Eldon and C. Simone Jude-Fishburn, who contribute to the research and development efforts at Nektar Therapeutics.

Conclusion

Myong Gyong Lee's contributions to the field of pharmacology, particularly through his patent on CYP2D6 alternative metabolizers, highlight his role as an innovator in addressing genetic variations in drug metabolism. His work continues to pave the way for advancements in personalized medicine.